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Abstract: MicroRNAs (miRNAs) have attracted heightened attention for their role as post-transcriptional regulators of 
gene expression. It has become clear that miRNAs can both up- and downregulate protein expression. According to cur-
rent estimates, most human genes are harboring miRNAs and/or are regulated by them. Thus miRNAs form a complex 
network of expression regulation which tightly interacts with known gene regulatory networks. Similar to some transcrip-
tion factors, some miRNAs can have hundreds of target transcripts whose expression they modulate. Thus miRNAs can 
form complex regulatory networks by themselves, but because their expression is often tightly coordinated with gene ex-
pression, they form an intertwined regulatory network with many possible interactions among gene and miRNA regula-
tory pathways. In this review we first consider gene regulatory networks. Then we discuss microRNAs and their implica-
tion in cancer and how they may form regulatory networks. Finally, we give our perspective and provide an outlook in-
cluding the aspect of personalized medicine. 
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INTRODUCTION 
 MicroRNAs (miRNAs) are short (~22 nts) nucleotide 
sequences that are usually co-transcribed during the produc-
tion of mRNA. Some miRNAs, however, are organized in 
intergenic regions and are exclusively transcribed by RNA 
polymerase II. The pre-miRNAs set themselves apart from 
other RNAs by their characteristic stem loop (hairpin) struc-
ture which appears important for their recognition during 
biogenesis, the process of maturation leading to functioning 
mature miRNAs. This is a multistep process taking place 
partially in the nucleus and in the cytosol. For more details 
on biogenesis, see chapters in the book miRNomics: Mi-
croRNA Biology and Computational Analysis edited by 
Allmer and Yousef (Methods in Molecular Biology, 2013).  
 MicroRNAs are potent regulators of protein expression. 
Although originally identified as negative post-transcriptional 
regulators of protein expression, since 2007 there has also 
been growing evidence for positive regulation of protein 
expression [1-4]. Gene regulation has long been known to be 
modulated in both directions and in retrospect it seems only 
logical that miRNAs should also be involved in both up and 
downregulation. 
 Since many miRNAs are co-transcribed with their source 
mRNAs, their expression levels correspond to each other. 
However, many additional regulation scenarios can apply to 
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miRNAs post-transcriptionally and thus lead to a deviation 
between gene expression and corresponding miRNA levels. 
Nonetheless, miRNAs, which are co-expressed with their 
source genes, may have a regulatory effect that is in-line, 
independent, contrary, or even self-directed when compared 
to the potential regulatory effect of the source gene (Fig. 1). 
Gene a (Fig. 1) harbors 4 miRNAs which are co-expressed 
with it. The miRNA miR-a targets the parent gene and causes 
its post-transcriptional repression while also downregulating 
itself.  
 Another miRNA (miR-b) has, indirectly, the same effect 
on the target gene of its parent (Gene b) and the regulations 
are thus in-line with each other. The miR-c has the same di-
rect effect on Gene d as its parent and the regulation is there-
fore coordinated. The miRNA miR-d has two targets one of 
which is not regulated by its parent gene (independent) while 
the regulation of the other (Gene b) is contrary to the effect 
its parent exhibits. In summary, (Fig. 1) gives an overview of 
different ways gene regulation and miRNA regulation can be 
coordinated. This will be discussed in more detail in the sec-
tion on Super Regulatory Networks.  
 It is known that gene or miRNA regulatory networks or 
any network in a cell do not exist in a void, but are intercon-
nected and, if one is perturbed, all work together to compen-
sate and to reestablish homeostasis [5]. This complexity is 
too vast to be covered here and therefore we will not detail 
protein interaction networks, signal transduction networks, 
or higher ecological views of networks. It is this complexity 
which imposes a great obstacle on pharmacogenomics, mak-
ing accurate predictions of global side effects currently im-
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possible since all interacting networks that contribute to the 
global system cannot currently be modeled. It has become 
clear that there is likely a role for all regions of a genome [6] 
and present modeling of regulation is probably imprecise 
since much information on regulation is still being uncov-
ered. 
 As mentioned above, there are a wide range of networks 
in a cell, for example: Gene regulatory, signal transduction, 
metabolic, and protein-protein interaction networks. It is 
futile to discuss all these interrelated issues here and, there-
fore, the focus is on gene and miRNA regulatory networks as 
well as their intersection. In the following we will first out-
line gene regulatory networks as far as they intersect with 
microRNA regulatory networks. 
GENE REGULATORY NETWORKS 
 The central dogma in molecular biology claimed that one 
gene leads to a single gene product [7]. With the discovery 
of alternative splicing, alternative start sites, and other modi-
fications such as RNA editing, it is now agreed that a gene 
can have many products. Additionally, genes can have by-
products such as miRNAs. Genes cannot interact with other 
genes other than via their gene products or byproducts. For 
the purpose of this work, genes can be considered nodes in a 
graph with their products being edges if they lead to an inter-
action with other genes (Fig. 2). For example, Wu and col-
leagues showed that the same gene can lead to the produc-
tion of pro- and anti-apoptotic factors due to alternative 
splicing (Fig. 2) [8]. 
REGULATORY PATHWAYS 
A regulatory pathway in biology describes the interaction 
among genes within a biological system. Since genes do not 
interact directly, they do so via their products which are, for 
example, proteins and miRNAs. A regulatory pathway is 
often triggered through a stimulus like the binding of a 
ligand to a receptor protein which causes the protein to set 
off a cascade of interactions with other proteins. Among 
these proteins are transcription factors which modulate gene 
expression. This leads to an increase or decrease of protein 
levels expressed by the affected genes. The whole process 
aims to elicit a cellular response appropriate for dealing with 
the initial event of binding a specific molecule. All parts of 
these often large and complicated pathways are candidate 
targets for pharmaceuticals. The importance of the pathway 
is two-fold. On one hand, knowledge of the pathway allows 
selection of a target and generation of drugs to change it. On 
the other hand, such knowledge allows prediction of the ef-
fects of modulating a member of the pathway. 
 The Kyoto Encyclopedia of Genes and Genomes 
(KEGG) provides, among other services, pathway interaction 
maps (http://www.genome.jp/kegg/pathway.html) and these 
represent how genes or their products perform metabolic 
processes [9, 10]. Since KEGG has been commercialized, 
other resources like Reactome [11] have been proposed to 
provide free access to pathway information. Reactome is not 
as comprehensive as KEGG, but we believe that with the 
current progress it will close the gap within the year 2014. 
These pathway databases are necessary as references for 
modeling and also to place additional information such as 
miRNA regulation into the proper perspective.  
RECONSTRUCTION, VISUALIZATION, AND NET-
WORK ANALYSIS/MODELING TOOLS 
 The visualization of networks in biology is usually quite 
similar to models in mathematical graph theory where a 
graph (G) is a set of vertices (V) connected by edges (E) 
such that G = (V, E). Vertices can, for example, represent 
genes or miRNAs or any other biological entity; while edges 
often signify upregulation or downregulation or any other 
kind or interaction among nodes (for an example see Fig. 1).  
 
 
Fig. (1). MicroRNA and gene regulation can have different types of effects (self, opposed, independent) for miRNAs from the perspective of 
a source gene (Gene a). They can also have similar or supporting effects (supporting, coordinated) from the same perspective. Connections 
without arrows depict that the miRNAs derive from the same transcript. Arrows indicate upregulation and terminal diamonds depict down-
regulation. 
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Fig. (2). Genes can be represented as nodes (ovals) and their inter-
actions via gene products can be represented as edges. Multiple 
edges originating from one node represent alternative gene prod-
ucts. Alternative product one inhibits “Gene b” (diamond) whereas 
alternative product 2 activates it (arrow head). 
 
 Visualization of regulatory networks has been a hallmark 
of KEGG but today there are numerous software programs 
which allow the modeling of graphs [12, 13]. Networks as 
described above are static. It is, however, important to allow 
for the application of mathematical models and for the inter-
section of different networks so that hypotheses can be 
tested. We believe that such software will become especially 
important in pharmacogenomics where they can help un-
cover side effects or point to new key players in the network 
to identify novel drug targets. 
 An extension of the simple network structure, that allows 
modeling and dynamics, are Petri nets which have two dif-
ferent types of vertices: one which represents a place (con-
taining some amount of a compound) and another which 
represents a transition (how a compound is transformed or 
acted upon). Places and processes are connected by directed 
edges (showing how compounds can be transmitted among 
the places) under the rule that places may not be connected 
and processes may not be linked directly (Fig. 3). 
 
 Petri nets are usually used for modeling in systems biol-
ogy, but they may also be used to simulate gene regulation 
(compare Fig. 1 and Fig. 3). To properly achieve that task, 
however, extensive measurements of gene, miRNA, and pro-
tein quantities are necessary to properly reconstruct even a 
small and simplified model as shown here. 
 Only a few of the software programs which offer graph 
visualization such as Cytoscape [14] also allow modeling 
using Petri nets [13]. We would like to highlight VANESA 
(http://vanesa.sourceforge.net/) here since it has many of the 
important features for network analysis such as Petri net 
modeling and a subscription to KEGG. In addition, we are 
currently working on the possibility of intersecting KEGG 
and miRNA regulatory networks so that the effect of miR-
NAs on other pathways and vice versa can be directly and 
visually investigated. Furthermore, VANESA allows the 
discovery of substructures (i.e. regulatory patterns) and the 
detection of hubs (i.e. key players in regulation). 
 The visualization, modeling, and analysis of graphs are 
important features, but network reconstruction may be the 
most important one because, only if a graph is successfully 
established, can it be analyzed in a meaningful manner. 
Some of the tools mentioned above (like VANESA), allow 
the reconstruction of networks with the aid of experimental 
data. Schlitt and Brazma caution, however, that the resulting 
networks are not equal and that, depending on their construc-
tion, they may fall into four categories [15]. These categories 
are: parts lists, topology models, control logic models, and 
dynamic models (the aforementioned Petri nets). They fur-
ther argue that it is important to know the limitations of the 
model employed to not overrate its predictions. 
MICRORNA REGULATORY NETWORKS 
 MicroRNAs or molecules mimicking them can poten-
tially be used as drugs while, on the other end of the spec-
trum, they can be drug targets by using, for example, an-
tisense RNA. One established application is their use as 
biomarkers for diagnostics [16]. MicroRNAs have also been 
tested as biomarkers in cancer [17]. Cancer is an important 
field of research and miRNAs have long played a role in 
cancer research. Satoh confirms that there are complex regu-
latory connections among proteins and miRNAs [18] and 
that this crosstalk is important in oncogenic signaling [19], 
especially for the E2F family proteins investigated in their 
studies [18, 19].  
 In the following we will discuss how miRNAs are in-
volved in tumor suppression and, adversely, also in invasion 
and formation of metastases. This seemingly Janus-like qual-
ity of haing two opposite faces, is not surprising considering 
that it is not a miRNA which causes cancer but the perturba-
tion of the overall network. Thus the same miRNA may po-
tentially be upregulated in one cancer and downregulated in 
another.  
IMPLICATIONS IN CANCER 
 Although it is well known that miRNAs regulate their 
targets, it is unclear how they do so cooperatively [20]. It has 
been shown; however, that a miRNA can regulate multiple 
targets and that one target can be regulated by multiple 
miRNAs. It could be speculated that one particular miRNA 
may partially downregulate some targets (although it may do 
so cooperatively with other miRNAs) while it could com-
pletely downregulate other targets. This opens the possibility 
to fine tune the regulation of protein expression using multi-
ple, potentially overlapping sensory pathways. As difficult as 
it is to elucidate the role of a particular miRNA and its tar-
gets, much progress has been made and we will first discuss 
some results where miRNAs can act as tumor suppressors. 
A MICRORNA CAN ACT AS TUMOR SUPPRESSOR 
 The roles of miRNAs in tumorigenesis, tumor invasion, 
and metastasis have been extensively described [21, 22]. The 
most well-known miRNAs involved in tumorigenesis are 
miR-15a, miR-16-1, let-7, the miR-29 family, the miR-17-92 
cluster, miR-21, and miR-155. These miRNAs can act as 
tumor suppressors and, when their functions are lost, the 
transformation of normal cells into malignant cells may be 
triggered. The cause of function loss may derive from ge-
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nomic changes including deletion [23], other mutations, epi-
genetic silencing, and other alterations [24, 25]. The miR-
NAs miR-15a and miR-16-1 were first observed with dele-
tion or downregulation in chronic lymphocytic leukemia [23, 
26]. The roles of these miRNAs have been further elucidated 
when an anti-apoptotic BCl-2 was found to be the target of 
these miRNAs [27, 28].  
 Another well-known miRNA family, let-7, was often 
found to be downregulated in tumors such as lung and breast 
cancer [29-31]. The let-7 family was found to target onco-
genes including the RAS family [30, 32], high mobility 
group A2 (HMGA2) [33], and MYC [34]. In lung cancer, 
expression of RAS and let-7 resulted in opposite patterns 
with low levels of let-7 and high levels of RAS in cancerous 
cells, while a high level of let-7 and a low level of RAS 
seems to be typical for normal cells [30]. let-7 also targets 
HMGA2 and the removal of HMGA’s 3’UTR region re-
sulted in HGMA2 overexpression and the induction of tumor 
formation [33]. Binding to the 3’UTR of an mRNA is a well-
accepted mode of action for a miRNA to regulate its target. 
 The miR-29 family consists of miRNAs, which form two 
clusters, miR-29b-1/miR-29a in chromosome locus 7q32 and 
mir-29b-2/miR-29c in chromosome locus 1q23. It has been 
shown that the chromosome locus 7q32 is frequently deleted 
in myelodysplasia acute myeloid leukemia [35]. In addition, 
the miR- 29 family members have been reported to be down-
regulated in chronic lymphocytic leukemia [26], lung [31] 
and breast cancer [29]. The miR-29 family members are 
known to target directly the myeloid leukemia cell differen-
tiation protein (MCL-1), anti-apoptotic member of the Bcl-2 
family of proteins [36], and the oncogene T-cell leuke-
mia/lymphoma 1 (TCL-1) [37]. Taken together, these factors 
may well explain the tumor suppressor effect. 
 The well-studied microRNA cluster miR-17-92 contains 
seven homologous miRNAs and has been identified to have 
oncogenic potential. These miRNAs target multiple genes 
responsible for both proapoptotic pathways and oncogenic 
activities [38, 39]. The oncogenic effects of the miR-17-92 
cluster have been shown to lead to the acceleration of c-
Myc-induced lymphoma development in a mouse model 
[38]. Furthermore, Bim, PTEN, and p21proteins were identi-
fied as targets of this miRNA cluster [39, 40]. In contrast, 
under some circumstances, this miRNA cluster might act as 
a tumor suppressor as in the case of inhibition to abolish 
Myc-induced cell proliferation and miR-17-5p repressed 
proliferation of breast cancer cells [41, 42]. 
 Unlike most other miRNAs which tend to be downregu-
lated in cancer cells, miR-21 is generally upregulated in a 
variety of cancer types [43]. Knockdown of miR-21 induced 
activation of caspases resulting in apoptosis of glioblastoma 
cells [44], activation of the p53 pathway, mediation of TGF-
β signaling induction, and eventual suppressed cell growth 
and increased apoptosis in glioblastoma cells [45]. In addi-
tion, knockdown of miR-21 also caused suppression of pro-
liferation in HeLa cells [46]. Downregulation of miR-21 
repressed cell growth in breast cancer cells through targeting 
 
 
Fig. (3). The transformation of Fig. 1 into one of many possible Petri net representations. Places are indicated by circles and processes by 
rectangles. Black dots depict available compounds in a place. All places are modeled to be discrete and all transitions are assumed to be con-
tinuous (both assumptions would probably not hold in reality and the fig is only for instructional purposes). 
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the PDCD4 tumor suppressor [47]. Recently, many tumor 
suppressors including, but not limited to PTEN, PDCD4, 
Tropomyosin, and Sprouty 1 have been experimentally vali-
dated [48].  
 The miR-155 also displays oncogenic activity and has 
been described in various cancers such as blood and breast 
cancer [49]. The miR-155 was first reported in the onco-
genesis of hematopoietic malignancies where it was found to 
be overexpressed in B-cell lymphomas and chronic lympho-
cytic leukemia [50]. Similarly, transgenic miR-155 in B-cells 
also resulted in acute lymphoblastic leukemia/high-grade 
lymphoma [51]. In breast cancer, the overexpression of miR-
155 was highly correlated with higher tumor grade and 
lymph node metastasis [52]. Treatment with a miR-155 an-
tisense construct inhibited growth, induced cell arrest in 
G0/G1 phase, enhanced apoptosis, and increased radio sensi-
tivity [52]. Furthermore, suppressor of cytokine signaling 1 
(socs1), a tumor suppressor - a negative feedback regulator 
of Janus activated kinase (JAK)/signal transducer and activa-
tor of transcription (STAT) signaling [53], has been pro-
posed to be a target of miR-155 in breast cancer cells [54]. It 
was further confirmed that the overexpression of miR-155 
caused repression of soc1, which induced cell proliferation, 
colony formation, and xenograft tumor growth in breast can-
cer cells [54]. In addition, miR-155 has also been found to be 
overexpressed in pancreatic [55, 56] and thyroid tumors [57].  
 As pointed out for the miR-17-92 cluster, miRNAs may 
present a dichotomy and may act as tumor suppressors or 
promote tumorigenesis, invasion, and metastasis.  
MICRORNAS CAN SUPPORT INVASION AND ME-
TASTASIS PROCESSES 
 Metastases are the main cause of cancer-related mortal-
ity. Metastasis begins when cells migrate from primary tu-
mors to neighboring cells and invade the basement mem-
brane. Recently, miRNAs have been shown to play critical 
roles in metastasis and the invasiveness of cancer cells [58], 
[59]. Although the oncogenic and tumor-suppressive roles of 
many miRNAs have been well characterized, the action of 
these miRNAs in mediating tumor metastasis have only re-
cently been addressed [60] and still remain largely under 
investigated [38, 49]. Among these, the most well character-
ized oncogenic miRNAs include miR-9, miR-10b, miR-107, 
miR-143, miR-151, miR-373, miR-375, and miR-520h. 
 The microRNA miR-9 acts as an oncogene or as a tumor 
suppressor [61]. It has been shown to be associated with the 
development of cancer metastasis [62-65]. However, silenc-
ing of miR-9 by cytosine-phosphate-guanine (CpG) island 
hypermethylation was found in many tumors [29, 66], which 
indicates that miR-9 can also act as a tumor suppressor. 
When miR-9 is upregulated in breast cancer, it directly tar-
gets CDH1, the E-cadherin-encoding messenger RNA, lead-
ing to an increase of cell motility and invasiveness [62]. The 
downregulation of CDH1 triggers activation of β -catenin 
signaling which is then followed by activation of the vascu-
lar endothelial growth factor (VEGF), finally leading to in-
creased tumor angiogenesis. In the non-metastasis model, 
overexpression of miR-9 caused development of pulmonary 
micrometastases in mice while inhibition of miR-9 had the 
opposite effect [62]. In addition, miR-9 also targets MYC 
and MYCN and the expression of miR-9/MYC/MYCN is 
highly correlated with tumor grade and metastasis status 
[62]. Recently, miR-9 was found to target the suppressor of 
cytokine signaling 5 (SOCS5) [67]. Overexpression of miR-
9 caused a reduction of SOCS5, leading to activation of the 
JAK-STAT pathway and promotion of endothelial cell mi-
gration and tumor angiogenesis [67]. Treatment with anti-
miR-9 inhibitors suppressed cell migration in vitro and de-
creased tumor burden in vivo [67]. In summary, miR-9 plays 
a crucial role in activation of cell migration and tumor angi-
ogenesis. 
 Another miRNA, miR-10b, has been described exten-
sively in respect to metastasis formation. Indeed, its expres-
sion correlates with high-grade malignancy in various types 
of cancer. In fact, it is highly expressed in metastasis status 
[68], hepatocellular carcinomas from metastasis-positive 
patients [65], and in pancreatic adenocarcinomas [69]. In 
breast cancer, overexpression of miR-10b triggered the for-
mation of metastasis and tumor invasion of a nonmetastatic 
human breast cancer cell line (SUM159 cells) and 
xenotransplantation models [60]. In addition, miR-10b also 
contributed to the progression of other types of cancer. For 
example, anti-miR-10b inhibitor caused reduction of cell 
proliferation, migration, and invasion in malignant peripheral 
nerve sheath tumor cells [70]. In esophageal cancer cells, 
overexpression of miR-10b increased cell motility and inva-
siveness, while inhibition of miR-10b reduced cell invasive-
ness [71]. Similar phenomena were observed with nude mice 
in nasopharyngeal carcinoma cells [72].  
 Unlike miR-10b, overexpression of miR-103/107 sup-
presses tumor angiogenesis, tumor growth, and tumor VEGF 
expression in mice with colon cancer [73]. Knockdown of 
endogenous miR-107 resulted in increasing HIF-1β expres-
sion and activation of hypoxic signaling, which is regulated 
by tumor suppressor gene TP53. More recently, miR-
103/107 have been found to target the known metastasis 
suppressors, death-associated protein kinase (DAPK) and 
Krüppel-like factor 4 (KLF4), in colorectal cancer cells [74]. 
In mouse models, overexpression of miR-103/107 caused 
reduction of DAPK and KLF4, leading to local invasion and 
liver metastasis effects, thus displaying the inverse correla-
tion of DAPK/KLF4 and miR-103/107. This has also been 
observed in patients with metastasis status [74]. Similarly, 
high expression levels of miR-103/107 were associated with 
metastasis and poor outcome in breast cancer [75]. Another 
interesting discovery of the mechanism of miR-107 was its 
ability to negatively regulate tumor suppressor miRNA let-7 
via direct interaction [76]. The miR-107 was highly ex-
pressed and its expression was reciprocal to expression of 
let-7 in both malignant tissues from patients and cell lines of 
breast cancer [76]. In contrast, the depletion of miR-107 
caused overexpression of let-7 in human and mouse breast 
cell lines.  
 The miR-143 represents one of the best-characterized 
oncogenes. It is located in a fragile region of the chromo-
some, often found to be deleted and its expression tends to 
be lower in many different types of cancers such as colon 
and gastric cancers as well as in B-cell lymphoma [77-79]. 
Overexpression of miR-143 inhibits cell proliferation in sev-
eral cancer cell lines [80, 81] and regulates contractile phe-
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notypes of murine vascular smooth muscle cells [82]. The 
oncogene KRAS was identified to be the target of miR-143 
[83].  
 The miR-151 localizes within the intron 22 of FAK (fo-
cal adhesion kinase) and it was often found to be overex-
pressed in human tumors and to promote cancer cell invasion 
and metastasis formation [84]. Overexpression of miR-151-
5p significantly enhanced cell migration and invasion in vi-
tro and in vivo in hepatocellular carcinoma [85]. In addition, 
miR-151 targets a putative metastasis suppressor, RhoGDIA, 
which leads to activation of Rac1, Cdc42 and Rho GTPases. 
Activation of this cascade induces cell mobility and spread-
ing which stimulates the transformation of tumor metastasis 
and invasion [85]. 
 More recently, using global miRNA expression profiling, 
Ding et al., identified that miR-375 is usually downregulated 
in gastric cancer as compared to adjacent non-tumor tissues 
[86]. Overexpression of miR-375 inhibited proliferation in 
both in vitro and in vivo studies of gastric cancer. The 
mechanism for the suppression in gastric cancer was further 
discussed when Janus kinase 2 (JAK2) was identified as a 
target of miR-375 [86]. Another cancerous inhibitor of PP2A 
(CIP2A), a guardian of the oncoprotein MYC, was also iden-
tified as a target for miR-375 by bioinformatic and experi-
mental methods [87]. Overexpression of miR-375 caused 
reduction of the expression of CIP2A resulting in a decrease 
of MYC protein levels, in turn leading to reduced prolifera-
tion, colony formation, migration, and invasion in oral can-
cer cells. This suggested that miR-375 could act as a tumor 
suppressor and that a low expression level contributes to 
transforming the cancerous phenotype [87]. 
 Using miRNA mimic screening and migration assay, 
Huang et al., found that miR-373 and miR-520c stimulate 
cancer cell migration and invasion in vitro and in vivo in 
breast cancer [88]. The migration activity has been suggested 
to be due to these miRNAs targeting CD44 for which ex-
pression correlations were found to be opposite [88]. Moreo-
ver, the miR-520/373 family inhibited NF-kB signaling by 
targeting RELA, leading to significantly reduced expression 
and secretion of the pro-inflammatory cytokines interleukin 
(IL)-6 and IL-8 [89]. Moreover, the miR-520/373 family 
suppressed transforming growth factor-b (TGF-b) signaling, 
Smad, plasminogen activator inhibitor-1, and angiopoietin- 
like 4 in vitro and in vivo [89]. Taken together, the miR-
520/373 family has a tumor-suppressive role and contributes 
to tumor progression and metastasis in breast cancer. 
CANCER REGULATORY NETWORKS 
 As described in detail above, it has been possible to inti-
mately link dysregulation of miRNA expression with many 
cancer types, cancer progression and invasiveness. Interest-
ingly, many miRNAs are ambivalent in their regulative out-
come. We attribute this to the fact that a single miRNA or 
gene product alone, may not suffice to explain a phenotype 
in cancer biology. We therefore suggest investigation of the 
intersection of gene and miRNA regulatory networks to 
achieve a more detailed and global view of cancer-related 
dysregulation. In the future, all these individual findings, as 
outlined above, must be viewed within the larger context of 
super regulatory networks. 
SUPER REGULATORY NETWORKS 
 MicroRNAs can originate from genes or can come from 
their own transcription units. In any case, their mode of ac-
tion is immediate, unlike genes which first have to be tran-
scribed and translated before their product performs an ac-
tion. Although it is at times beneficial to investigate local 
effects of expression changes, the results only provide sig-
nificant benefits in the larger context of the suitable regula-
tory network. By extension, the same is true for regulatory 
networks which may be so intertwined that they cannot be 
treated separately. In line with this, Zhou and colleagues 
pointed out the importance of a combined miRNA and gene 
regulatory network, but acknowledged that, at times, it is 
beneficial to investigate the two networks independently 
[20]. On the other hand, many subnetworks may be redun-
dant and can thus replace each other functionally and could 
be investigated separately. Even though all regulatory levels 
come together to achieve homeostasis, some key players may 
exist in the super regulatory network and influencing them 
may compromise homeostasis. However, the reconstruction 
of regulatory networks is a complex task.  
NETWORK RECONSTRUCTION 
 The building of a gene or a miRNA regulatory network 
independently is not a trivial task and constructing a com-
bined network is even more difficult. Li and colleagues used 
parallel miRNA and mRNA expression datasets from 
CellMiner [90], mirGen [91] for miRNA-gene relationships, 
and TRED [92] for transcription factor (TF) - gene relations-
hips. From the combined data, they derived the TF-miRNA 
interactions using a number of assumptions and heuristics 
[93]. This seems to be the minimum amount of information 
needed to reconstruct a TF, gene, and miRNA network. 
Some caveats of this study are that some of the data seems to 
be outdated and could be enhanced with integrating informa-
tion from competing databases and that no proteomics data is 
available and thus no proof on the protein level is possible.  
 In straightforward gene regulation, a gene leads to a 
product which then modulates the expression of other genes. 
However, Schlitt and Brazma argue that a gene product may 
not be able to achieve this regulation alone and must bind 
some other compound before. This involves a binding inter-
action; one among several types of relationship among the 
graph nodes (edge) that they were able to identify [15]. An-
other relationship that is not intuitive on a biological level is: 
‘has similar sequence’, but for network reconstruction with 
unknown and known sequences, it may be useful to construct 
such interactions. Many other edges, such as biologically 
intuitive ones like ‘activates’, ‘silences’, and ‘degrades’, or 
computationally necessary ones like ‘is cocited’, ‘is structur-
ally similar’, and ‘provides evidence’ constitute a recon-
structed network. 
 A network pattern is a recurring subgraph and two well-
known regulatory patterns are feed-forward and feedback 
loops. For more information on network motifs please refer 
to [94]. Wingender and colleagues investigated which pat-
terns concerning TF and miRNAs are present in different 
human tissues [95]. They were able to identify some com-
mon patterns (limited to three genes) but also regulatory mo-
tifs which are only found in subsets of tissue-specific recon-
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structed networks. Interestingly, they found that the more 
tissue specific motifs usually contain miRNAs whereas the 
common patterns usually do not. Concerning larger patterns, 
they found different bowtie structures noteworthy. Wingen-
der and colleagues pointed out that most of the small motifs 
that they found represent feed-forward patterns [95] and it is 
interesting in this context to see that the oncomir miR-24-1 
may be in a negative feedback loop [96]. Herranz and Cohen 
also described multiple uses of feedback motifs in nature 
[97]. In a large scale reconstruction, Li and colleagues found 
that only 5 of 18 possible small motifs consisting of one TF, 
one gene, and one miRNA significantly recurred in the net-
work. Among these was only one feedback motif [93].  
DISCUSSION 
 It is now clear that miRNA expression is closely associ-
ated with tumorigenicity, invasion and metastasis [98]. Wu 
further elaborates on the use of miRNAs as biomarkers, 
drugs, or drug enhancers [98]. Some new creative strategies 
of the use of miRNAs as drugs are miRNA mimics [99], 
multiple-target anti-miRNAs [100], and chemical inhibitors 
[101] as mentioned by [98]. The potential of miRNAs to 
function as drugs or drug targets is as broad as the spectrum 
of miRNA functions. This spectrum is huge since, according 
to recent estimates, up to 90% of human genes may be regu-
lated by miRNAs [102]. We are currently establishing a full 
network of miRNAs and their targets in human and believe 
that the regulation is well beyond 100% which means that 
one or multiple miRNAs independently or synergistically 
regulate multiple human genes (Hamzeiy et al, in prepara-
tion).  
 The expression of many miRNAs is regulated by tran-
scription factors while miRNAs reciprocally modulate the 
expression of many TFs. This fact establishes the link be-
tween miRNA and conventional gene regulatory networks. 
This link is difficult to establish in practice, but if a miRNA 
can be placed into a regulatory circuit, it becomes possible to 
understand its mode of action [97]. The miRNA and gene 
regulatory systems are designed to maintain robust function 
in face of external perturbations [103] and miRNAs strongly 
contribute to this robustness [104]. In addition to miRNA 
directed regulation and gene regulation, there are other ways 
for a cell to achieve homeostasis. For example, the half-life 
of any product directly influences its regulatory potential and 
the half-life can be dependent on the environment or on other 
stabilizing/ destabilizing molecules. Thus, any drugs target-
ing the complex interwoven regulatory network may have 
unexpected effects. In conclusion, these studies and com-
bined network analysis tools can facilitate the investigation 
of short and long range effects upon the expression or func-
tion of gene products or miRNAs once proper super regula-
tory networks can be reconstituted. 
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